<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25056901</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>19</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response.</ArticleTitle><Pagination><StartPage>11356</StartPage><EndPage>11368</EndPage><MedlinePgn>11356-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01400-14</ELocationID><Abstract><AbstractText Label="UNLABELLED">Retinoic acid-inducible gene I (RIG-I) is an intracellular RNA virus sensor that induces type I interferon-mediated host-protective innate immunity against viral infection. Although cylindromatosis (CYLD) has been shown to negatively regulate innate antiviral response by removing K-63-linked polyubiquitin from RIG-I, the regulation of its expression and the underlying regulatory mechanisms are still incompletely understood. Here we show that RIG-I activity is regulated by inhibition of CYLD expression mediated by the microRNA miR-526a. We found that viral infection specifically upregulates miR-526a expression in macrophages via interferon regulatory factor (IRF)-dependent mechanisms. In turn, miR-526a positively regulates virus-triggered type I interferon (IFN-I) production, thus suppressing viral replication, the underlying mechanism of which is the enhancement of RIG-I K63-linked ubiquitination by miR-526a via suppression of the expression of CYLD. Remarkably, virus-induced miR-526a upregulation and CYLD downregulation are blocked by enterovirus 71 (EV71) 3C protein, while ectopic miR-526a expression inhibits the replication of EV71 virus. The collective results of this study suggest a novel mechanism of the regulation of RIG-I activity during RNA virus infection by miR-526a and suggest a novel mechanism for the evasion of the innate immune response controlled by EV71.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">RNA virus infection upregulates the expression of miR-526a in macrophages through IRF-dependent pathways. In turn, miR-526a positively regulates virus-triggered type I IFN production and inhibits viral replication, the underlying mechanism of which is the enhancement of RIG-I K-63 ubiquitination by miR-526a via suppression of the expression of CYLD. Remarkably, virus-induced miR-526a upregulation and CYLD downregulation are blocked by enterovirus 71 (EV71) 3C protein; cells with overexpressed miR-526a were highly resistant to EV71 infection. The collective results of this study suggest a novel mechanism of the regulation of RIG-I activity during RNA virus infection by miR-526a and propose a novel mechanism for the evasion of the innate immune response controlled by EV71.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Changzhi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zirui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Congwen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Lihua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Buchang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Health Science, School of Life Sciences, AnHui University, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, General Hospital of Jinan Military Region, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shengli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Penghao</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Pingping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China Department of Laboratory Medicine, General Hospital of Jinan Military Region, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Quanbin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Youguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China xyang@nic.bmi.ac.cn towall@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China xyang@nic.bmi.ac.cn towall@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>120904-94-1</RegistryNumber><NameOfSubstance UI="D025821">Polyubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="C409984">CYLD protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D000074749">Deubiquitinating Enzyme CYLD</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C452820">RIGI protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053487" MajorTopicYN="N">DEAD-box RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074749" MajorTopicYN="N">Deubiquitinating Enzyme CYLD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="Y">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025821" MajorTopicYN="N">Polyubiquitin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25056901</ArticleId><ArticleId IdType="pmc">PMC4178780</ArticleId><ArticleId IdType="doi">10.1128/JVI.01400-14</ArticleId><ArticleId IdType="pii">JVI.01400-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palacios G, Oberste MS. 2005. Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11:424&#x2013;433. 10.1080/13550280591002531</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280591002531</ArticleId><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26:91&#x2013;107. 10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral PM, Morrison JM, Drahos J, Gupta P, Sarkar D, Fisher PB, Racaniello VR. 2007. MDA-5 is cleaved in poliovirus-infected cells. J. Virol. 81:3677&#x2013;3684. 10.1128/JVI.01360-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01360-06</ArticleId><ArticleId IdType="pmc">PMC1866155</ArticleId><ArticleId IdType="pubmed">17267501</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral PM, Sarkar D, Fisher PB, Racaniello VR. 2009. RIG-I is cleaved during picornavirus infection. Virology 391:171&#x2013;176. 10.1016/j.virol.2009.06.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.045</ArticleId><ArticleId IdType="pmc">PMC2743091</ArticleId><ArticleId IdType="pubmed">19628239</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KG, Coyne CB. 2013. Enter at your own risk: how enteroviruses navigate the dangerous world of pattern recognition receptor signaling. Cytokine 63:230&#x2013;236. 10.1016/j.cyto.2013.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2013.05.007</ArticleId><ArticleId IdType="pmc">PMC3987772</ArticleId><ArticleId IdType="pubmed">23764548</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2012. Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection. J. Virol. 86:5541&#x2013;5553. 10.1128/JVI.00114-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00114-12</ArticleId><ArticleId IdType="pmc">PMC3347272</ArticleId><ArticleId IdType="pubmed">22379090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Sun Z, Liu X, Jin Q, He B, Wang J. 2011. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J. Virol. 85:8811&#x2013;8818. 10.1128/JVI.00447-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00447-11</ArticleId><ArticleId IdType="pmc">PMC3165803</ArticleId><ArticleId IdType="pubmed">21697485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Xiao X, Xue Q, Jin Q, He B, Wang J. 2013. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. J. Virol. 87:1690&#x2013;1698. 10.1128/JVI.01855-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01855-12</ArticleId><ArticleId IdType="pmc">PMC3554134</ArticleId><ArticleId IdType="pubmed">23175366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF, He ML. 2012. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J. Virol. 86:3767&#x2013;3776. 10.1128/JVI.06687-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06687-11</ArticleId><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499&#x2013;511. 10.1038/nri1391</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1391</ArticleId><ArticleId IdType="pubmed">15229469</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E, Tschopp J. 2006. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22:561&#x2013;569. 10.1016/j.molcel.2006.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.05.012</ArticleId><ArticleId IdType="pubmed">16762830</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. 2006. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7:1250&#x2013;1257. 10.1038/ni1412</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1412</ArticleId><ArticleId IdType="pubmed">17110941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981&#x2013;988. 10.1038/ni1243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1243</ArticleId><ArticleId IdType="pubmed">16127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730&#x2013;737. 10.1038/ni1087</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1087</ArticleId><ArticleId IdType="pubmed">15208624</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. 2005. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19:727&#x2013;740. 10.1016/j.molcel.2005.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2005.08.014</ArticleId><ArticleId IdType="pubmed">16153868</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi B, Huang Y, Rowe D, Halliday G. 2007. VISA&#x2014;a pass to innate immunity. Int. J. Biochem. Cell Biol. 39:287&#x2013;291. 10.1016/j.biocel.2006.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.08.016</ArticleId><ArticleId IdType="pubmed">17029998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Sun L, Liu HH, Chen X, Seth RB, Forman J, Chen ZJ. 2006. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 24:633&#x2013;642. 10.1016/j.immuni.2006.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.04.004</ArticleId><ArticleId IdType="pubmed">16713980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiscott J, Lin R, Nakhaei P, Paz S. 2006. MasterCARD: a priceless link to innate immunity. Trends Mol. Med. 12:53&#x2013;56. 10.1016/j.molmed.2005.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2005.12.003</ArticleId><ArticleId IdType="pubmed">16406812</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122:669&#x2013;682. 10.1016/j.cell.2005.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.08.012</ArticleId><ArticleId IdType="pubmed">16125763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S. 2000. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25:160&#x2013;165. 10.1038/76006</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/76006</ArticleId><ArticleId IdType="pubmed">10835629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wu X, Lee AJ, Jin W, Chang M, Wright A, Imaizumi T, Sun SC. 2008. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J. Biol. Chem. 283:18621&#x2013;18626. 10.1074/jbc.M801451200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M801451200</ArticleId><ArticleId IdType="pmc">PMC2441564</ArticleId><ArticleId IdType="pubmed">18467330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:797&#x2013;801. 10.1038/nature01811</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01811</ArticleId><ArticleId IdType="pubmed">12917690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801&#x2013;805. 10.1038/nature01802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01802</ArticleId><ArticleId IdType="pubmed">12917691</ArticleId></ArticleIdList></Reference><Reference><Citation>Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793&#x2013;796. 10.1038/nature01803</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01803</ArticleId><ArticleId IdType="pubmed">12917689</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. 2006. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125:665&#x2013;677. 10.1016/j.cell.2006.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.03.041</ArticleId><ArticleId IdType="pubmed">16713561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. 2009. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 183:2150&#x2013;2158. 10.4049/jimmunol.0900707</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900707</ArticleId><ArticleId IdType="pubmed">19596990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahid MA, Satoh M, Chan EK. 2011. MicroRNA in TLR signaling and endotoxin tolerance. Cell. Mol. Immunol. 8:388&#x2013;403. 10.1038/cmi.2011.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2011.26</ArticleId><ArticleId IdType="pmc">PMC3618661</ArticleId><ArticleId IdType="pubmed">21822296</ArticleId></ArticleIdList></Reference><Reference><Citation>Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J. Virol. 77:1501&#x2013;1511. 10.1128/JVI.77.2.1501-1511.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.2.1501-1511.2003</ArticleId><ArticleId IdType="pmc">PMC140815</ArticleId><ArticleId IdType="pubmed">12502864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Yang X, Wang Y, Wen C, Wu Q, Shi W, Zhong H. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J. Immunol. 185:1158&#x2013;1168. 10.4049/jimmunol.0903874</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903874</ArticleId><ArticleId IdType="pubmed">20554965</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x2212;&#x394;&#x394;CT) method. Methods 25:402&#x2013;408. 10.1006/meth.2001.1262</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Eisenacher K, Kirchhofer A, Brzozka K, Lammens A, Lammens K, Fujita T, Conzelmann KK, Krug A, Hopfner KP. 2008. The C-terminal regulatory domain is the RNA 5&#x2032;-triphosphate sensor of RIG-I. Mol. Cell 29:169&#x2013;179. 10.1016/j.molcel.2007.10.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2007.10.032</ArticleId><ArticleId IdType="pubmed">18243112</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuro A, Bamming D, Horvath CM. 2008. Negative regulation of cytoplasmic RNA-mediated antiviral signaling. Cytokine 43:350&#x2013;358. 10.1016/j.cyto.2008.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.07.011</ArticleId><ArticleId IdType="pmc">PMC2575845</ArticleId><ArticleId IdType="pubmed">18703349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Tian Y, Wang RP, Gao D, Zhang Y, Diao FC, Chen DY, Zhai ZH, Shu HB. 2008. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell Res. 18:1096&#x2013;1104. 10.1038/cr.2008.277</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2008.277</ArticleId><ArticleId IdType="pubmed">18711448</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S. 2009. Innate immunity to virus infection. Immunol. Rev. 227:75&#x2013;86. 10.1111/j.1600-065X.2008.00737.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00737.x</ArticleId><ArticleId IdType="pmc">PMC5489343</ArticleId><ArticleId IdType="pubmed">19120477</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9:930&#x2013;936. 10.1038/embor.2008.136</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2008.136</ArticleId><ArticleId IdType="pmc">PMC2529351</ArticleId><ArticleId IdType="pubmed">18636086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M, Sasaki K. 2004. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Modern Pathol. 17:617&#x2013;622. 10.1038/modpathol.3800107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.3800107</ArticleId><ArticleId IdType="pubmed">15133472</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. 2007. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28:21&#x2013;27. 10.1093/carcin/bgl081</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgl081</ArticleId><ArticleId IdType="pubmed">16774947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. 2007. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110:3291&#x2013;3300. 10.1182/blood-2007-02-075069</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-075069</ArticleId><ArticleId IdType="pubmed">17609426</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. 2005. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e179. 10.1093/nar/gni178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gni178</ArticleId><ArticleId IdType="pmc">PMC1292995</ArticleId><ArticleId IdType="pubmed">16314309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitsiou E, Lindsay MA. 2009. MicroRNAs and the immune response. Curr. Opin. Pharmacol. 9:514&#x2013;520. 10.1016/j.coph.2009.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2009.05.003</ArticleId><ArticleId IdType="pmc">PMC2742742</ArticleId><ArticleId IdType="pubmed">19525145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Ke X, Wang M, He S, Li Q, Zheng C, Zhang Z, Liu Y, Wang H. 2013. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J. Virol. 87:5645&#x2013;5656. 10.1128/JVI.02655-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02655-12</ArticleId><ArticleId IdType="pmc">PMC3648165</ArticleId><ArticleId IdType="pubmed">23468506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>